Relay Therapeutics is trading at $17.44, down -4.96%, with biotech-sector pressure a possible factor in the decline.
- The provided sector context shows XBI down 2.39%, while major-index context is positive.
- No clear company-specific news explaining the November 2 decline was identified.
- Third-quarter results are scheduled for November 4; this is not a reported result or new catalyst.